Compare ETG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ETG | NNNN |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | ETG | NNNN |
|---|---|---|
| Price | $23.40 | $21.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 132.1K | 37.3K |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | ★ 6.64% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $6,920,153.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $386.55 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.08 | $5.18 |
| 52 Week High | $18.34 | $55.65 |
| Indicator | ETG | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 61.16 | 35.63 |
| Support Level | $22.45 | $28.61 |
| Resistance Level | $23.47 | $31.52 |
| Average True Range (ATR) | 0.23 | 4.86 |
| MACD | -0.02 | -1.64 |
| Stochastic Oscillator | 90.21 | 10.10 |
Eaton Vance Tax Advgd Gbl Div Inc Fd is a diversified, closed-end management investment company. Its investment objective is to provide a high level of after-tax total return consisting of tax-advantaged dividend income and capital appreciation. The fund pursues its objective by investing in dividend-paying common and preferred stocks. Its portfolio of investments consists of aerospace and defense, capital markets, diversified telecommunication services, electrical equipment, biotechnology, banks, and other areas.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.